The Pedro J. Romero Award recognizes individuals who have made outstanding contributions to the cancer immunotherapy field Second SITC award this year to Professor Melief who will be honoured at the 37th SITC Annual Meeting Oegstgeest, 8 September 2022 – ISA is delighted to announce that our CSO Professor Dr. Cornelis “Kees” Melief has been awarded the 2022 Pedro […]
7 September 2022, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the biotechnology company discovering and developing novel small molecule therapies targeting RNA modification enzymes for oncology and other diseases, today announced the appointment of Dr. Gerald (Jerry) McMahon as President and Chief Executive Officer and Board Director. Read more…
Recognition of commendable, longstanding dedication to the field of cancer immunotherapy Oegstgeest, 15 July 2022 – ISA is delighted to announce that our Chief Scientific Officer (CSO) and Founder, Professor Dr. Cornelis “Kees” Melief has been nominated and selected by the Board of Directors of the Society for Immunotherapy of Cancer (SITC) as a Fellow of the Academy of […]
BERLIN, 7 July 2022 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and systemic targeted radiation therapy of certain hard-to-treat cancers, is pleased to announce the appointment of Serge Sagodira as Chief Business Officer. Appointed from 1 July 2022, Serge will oversee all business development aspects of the company, leveraging […]
Destiny Pharma announces start of a new XF-73 research programme Aim to test XF-73 as a potential preventive medicine for Oral Mucositis Oral Mucositis is a common and devastating complication from chemotherapy and radiotherapy suffered by more than 2m cancer patients every year Brighton, United Kingdom – 05 July 2022 – Destiny Pharma plc (AIM: DEST), […]
